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Original Article
INTRODUCTION
Epistaxis is one of the most common otorhinolaryngologic emer-
gencies representing more than 12% of conditions managed at 
Ear, Nose and Throat (ENT) Emergency Consulting Room (ECR) 
of our Otorhinolaryngologic Unit each year. It affects up to 60% 
of the population during their lifetime, with 6% requiring medi-
cal attention [1-5]. It is more common in the older population 
[2]; the greatest peaks in the overall incidence occur in individu-
als under 10 years of age and over 40 years of age [6].
The most common etiology is idiopathic [6]; in 80%–90% of 
cases, no precipitating causes can be identified [2,5]. Of the other 
identifiable causes of epistaxis, the most frequent are trauma, na-
sal neoplasm, iatrogenic or due to systemic factors (hypertension, 
coagulopathy, inflammatory conditions, infectious diseases, vessel 
wall fibrosis in the tunica media associated with ageing), use of 
drugs (anticoagulant, antiplatelet, nonsteroidal anti-inflammatory, 
 • Received March 10, 2015  
Revised April 24, 2015 
Accepted May 6, 2015 
 • Corresponding author: Paolo Farneti  
Ear, Nose and Throat Unit of Sant’Orsola-Malpighi Hospital, Via Albertoni 
15, Biblioteca Otorino Pad. 5, 40138 Bologna, Italy  
Tel: +39-3391460515, Fax: +39-0516363525 
E-mail: paolo.farneti5@unibo.it
pISSN 1976-8710   eISSN 2005-0720
Comparison of Local Sclerotherapy With 
Lauromacrogol Versus Nasal Packing in the 
Treatment of Anterior Epistaxis
Paolo Farneti1,2·Ernesto Pasquini3·Vittorio Sciarretta2·Giovanni Macrì2·Giulia Gramellini2·Antonio Pirodda1,2
1Department of Experimental, Diagnostic and Specialty Medicine, Bologna University Medical School, Bologna; 2Ear, Nose and Throat Unit of 
Sant’Orsola-Malpighi Hospital, Bologna; 3Ear, Nose and Throat Metropolitan Unit, Azienda Unità Sanitaria Locale di Bologna, Bologna, Italy
Objectives. Epistaxis is one of the most common otorhinolaryngologic emergencies representing more than 12% of condi-
tions managed at the Ear, Nose and Throat (ENT) Emergency Consulting Room of our Otorhinolaryngologic Unit 
each year. The elevated frequency of this pathology makes it necessary to adopt the most effective and least expen-
sive therapeutic strategy available. The aim of this study was to compare the efficacy, costs and morbidity of nasal 
packing (NP), which is the mainstay of treatment for anterior epistaxis in our ENT Emergency Consulting Room ver-
sus submucosal infiltrations of lauromacrogol (LA).
Methods. A retrospective study was designed from August 2012 to April 2013 involving 53 patients suffering from anterior 
epistaxis. Anterior NP was used in 27 patients versus 26 patients undergoing 27 procedures performed with submu-
cosal infiltrations of LA (or polidocanol). Outcomes for each treatment were evaluated. Patients in group 1 were 
treated with LA 400 injection next to the bleeding point: 0.5- to 1-mL single or multiple infiltrations with a 27-gauge 
needle. The whitening of the nasal mucosa around the bleeding point during infiltration was considered a marker of 
correct procedure in order to achieve the best results. Bilateral treatment was also performed at the same time. Pa-
tients in group 2 were treated with standard NP.
Results. Bleeding recurrence was higher in the NP group even if it was not statistically significant (P=0.2935). However, 
the LA infiltrations were better tolerated with lower morbidity and costs as compared to NP. No complications were 
observed in either group.
Conclusion. LA infiltrations were shown to be a viable alternative in anterior epistaxis treatment. They are safe, easy to use 
with good efficacy and have a low cost.
Keywords. Epistaxis; Sclerotherapy; Polidocanol; Nasal Mucosa; Polyethylene Glycol
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nasal sprays) and congenital nasal septal abnormalities [2,6].
 Epistaxis is classified as anterior or posterior on the basis of 
the primary bleeding site [7]. Anterior bleeds are the most com-
mon (80%–95%) [2,5] and occur from the anterior nasal area, 
also known as Kiesselbach’s plexus (or Little’s area or locus Val-
salvae), which is anatomically formed by the anastomosis be-
tween the terminal branches of the external and internal carotid 
arteries. 
 The high incidence of epistaxis in the general population rep-
resents a significant healthcare cost and presents us with the op-
portunity of modifying the cost-benefit equation by adopting ef-
fective management strategies [8]. The aim of this study was to 
compare the efficacy, costs and morbidity of nasal packing (NP), 
which is the mainstay of treatment for anterior epistaxis in our 
ENT ECR, versus submucosal infiltrations of lauromacrogol (LA).
 Lauromacrogol (or polidocanol) is a polyethylene glycol 
monododecyl ether, which has a selective effect on the venous 
endothelium, leading to a secondary thrombosis without necro-
sis in the surrounding tissue, providing this is healthy and well 
irrigated. At the end of the process, the obliterated vein is re-
placed with connective fibrous tissue. As it is a stable compound 
at room temperature and has low viscosity, its administration is 
very simple and efficient in intralumen, submucosal infiltrations. 
It is commercially available as Aethoxysklerol (Kreussel Pharma, 
Chemische Fabrik Kreussler & Co., Wiesbaden, Germany) and 
comes in boxes containing five 2-mL vials. We use vials of 1% 
which contain 20 mg of LA 400. Vials of 0.25%, 0.5%, 2%, and 
3% are also available, with a total amount of LA of 5, 10, 40, 
and 60 mg, respectively. 
 Fifty-three patients suffering from anterior epistaxis were 
studied from August 2012 to April 2013. Anterior NP was ap-
plied in 27 patients versus 26 patients undergoing 27 procedures 
using submucosal infiltrations of LA. In both groups, efficacy, 
tolerance, complications and costs of treatment were analyzed.
MATERIALS AND METHODS
A retrospective study was designed involving patients with an 
anterior bleed from Kiesselbach’s plexus (which had not been 
resolved with the common method of applying pressure to this 
area) diagnosed and treated at the ENT ECR of our Otorhino-
laryngologic Clinic from August 2012 to April 2013.
 In order to avoid any bias, related to the choice of the treat-
ment, only cases treated by 2 operators were selected. During 
the period of the study, despite the severity of the case, it was 
found that one operator performed only submucosal infiltrations 
of LA while the other performed only NP.
 Patients eligible for the study were retrospectively divided 
into 2 groups. The patients in group 1 (LA group) were those 
treated with submucosal infiltration of LA by one operator 
while the patients in group 2 (NP group) were those undergoing 
NP performed by a second operator.
 Admission criteria: Only patients with anterior and localizable 
epistaxis in Kiesselbach’s plexus were enrolled. Exclusion crite-
ria: (1) secondary epistaxis (posttraumatic, postoperative, tu-
moral); (2) age less than 18 years; (3) pregnancy; (4) major sys-
temic disease; (5) hereditary hemorrhagic telangiectasia (HHT); 
(6) lack of data in patient’s chart.
 Epistaxis related to pharmacological therapy (anticoagulant) 
or to hypertension was not excluded.
 In both treatments, the nasal cavity affected was first treated 
with cotton soaked with a few drops of a solution of lidocaine 
hydrochloride monohydrate 5.3 g and naphazoline nitrate 0.020 
g ×100 mL (Xylocaine 5%, Astra Zeneca, Rueil-Malmaison, 
France) for a few minutes. This was used to obtain local anesthe-
sia and nasal mucosae decongestion in order to reduce the bleed-
ing and to better visualize the bleeding site. When necessary, a 
nasal endoscopy was also performed to exclude posterior bleed-
ing and to obtain a better view of the anterior nasal mucosae. 
 The LA injection technique: 0.5- to 1-mL single or multiple 
submucosal infiltrations next to the bleeding point using a 
27-gauge needle. Submucosal infiltration instead of subpericon-
drial infiltration was preferred in order to achieve a better out-
come (the venous endothelium is located in the submucosal re-
gion) and to avoid septal cartilage necrosis. The whitening of the 
nasal mucosa around the bleeding point during infiltration was 
considered as a marker of correct procedure in order to achieve 
the best results. In patients with bilateral anterior epistaxis bilat-
eral treatment was also performed at the same time. When there 
was persistence of bleeding from the site of the injection, a 
smooth NP with Gelita-Spon (Absorbable Gelatin Sponge, Geli-
ta Medical, Amsterdam, The Netherlands) was carried out.
 Infiltrations can be repeated when there is persistence of an 
exophytic septal vessel, even if asymptomatic, or in the case of 
persistence of bleeding.
 Nasal packing: performed with short 4.5 cm or long 8 cm 
Merocel standard nasal dressing (Medtronic Xomed Inc., Jack-
sonville, FL USA). In some cases Merocel NP was used in com-
bination with hyaluronic acid gauze pads.
 No prophylactic systemic antibiotics were systematically pre-
scribed in either group of patients. The patients were checked 
after 72 hours by the resident on duty in order to remove the 
NP or to evaluate the short-term results of the infiltration. After 
this follow-up, the patients were asked (by means of a telephone 
interview) to report any recurrence of epistaxis (and how it was 
treated) and any possible complication occurring during the first 
month after treatment, and to complete a questionnaire regard-
ing treatment morbidity. Bleeding after thirty days was no lon-
ger considered as a recurrence.
 The following were evaluated: 
 (1) the efficacy of the treatment after 3 days and after 1 month
 (2)  the treatment morbidity using a specific questionnaire: (i) 
with a numeric rating scale (NRS-11) which is an 11-point 
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scale for self-reported pain during the execution of the 
treatment (ii) with a numeric rating scale from 0 to 5 to 
evaluate the most frequent symptoms during the first 72 
hours after treatment (nasal congestion, epiphora, pain or 
headache, other).
 (3) complications arising in the first month after the procedure
 (4) cost of each procedure (excluding costs common to both)
 Statistical analysis was carried out using SAS ver. 9.3. (SAS 
Inc., Cary, NC, USA). The Fisher exact test and Wilcoxon rank 
sum test (Mann-Whitney U-test) were used to compare the re-
sults.
 This study was approved by our Institution Review Board 
(protocol number: 1585/2014).
RESULTS
Lauromacrogol (LA group)
Twenty-seven procedures using submucosal infiltration of LA 
were performed on 26 patients eligible for the study; one of 
these patients had a bilateral infiltration at the same time due to 
bilateral epistaxis.
 There were 16 males and 10 females (male/female ratio, 
1.6/1) and the mean age was 63±21 years ranging from 18 to 
88 years, with a median value of 66 years.
 The mean number of injections was 1.89 with a mean use of 
LA of 0.68 mL per procedure. In the majority of cases 
(66.66%), after treatment, the nasal cavity was packed with re-
sorbable material Gelita-Spon (Absorbable Gelatin Sponge, 
Gelita Medical, Amsterdam, The Netherlands) positioned only 
over the bleeding site: in the remaining cases there was no need 
to position any resorbable packing. This material was used to 
avoid any possible bleeding from the injection site during the 
first hours after the procedure and to permit the safe return 
home of the patient after discharge, especially for the older pa-
tients if under anticoagulant therapy.
 Three patients were excluded from our series because the na-
sal cavity was packed with a short Merocel for 48 hours after 
infiltration. The use of such NP in these cases was justified by el-
evated blood pressure or anticoagulant therapy associated with 
advanced age (all over 84 years of age). In these patients, there 
was a high risk of a recurrence of bleeding which could repre-
sent a serious social and management problem.
 The frequency of hypertension in the group selected was 
61.54%, and 30.77% of the patients were under warfarin or as-
pirin therapy.
 In 3 cases (11.11%), there was a recurrence of epistaxis 
which occurred after 3–13 days (mean, 9 days); it was treated 
with anterior NP. All patients suffered from uncontrolled hyper-
tension, and 1 patient was under aspirin treatment. 
 In 2 of these cases, after the removal of the NP, there were no 
more bleeding episodes. In the last case, the patient underwent 
bipolar cautery one month after the first episode.
 The 3-day follow-up showed some minor self-contained bleeding 
in 3 cases (11.11%) and some crust formation in 3 cases (11.11%).
Nasal packing (NP group)
Twenty-seven treatments with NP were performed on 27 pa-
tients eligible for the study. There were 14 males and 13 females 
(male/female ratio 1.08/1) and the mean age was 75±18 years 
ranging from 20 to 96 years, with a median value of 79 years.
 In 8 cases, due to the presence of a septal spur, standard 
packing with short or long Merocel was associated with the use 
of hyaluronic acid gauze pads; this helped to achieve a more ef-
ficient control of the bleeding in these cases.
 NP was always removed approximately 72 hours after treat-
ment in order to reduce patient’s discomfort and to avoid the 
use of antibiotics (normally advisable for longer packing).
 The prevalence of hypertension in the group selected was 
81.48%, and 59.26% of patients were under warfarin or aspirin 
therapy.
 Seven patients had a recurrence of epistaxis (25.93%): all pa-
tients suffered from uncontrolled hypertension, and 4 patients 
were under anticoagulant treatment. One patient returned to 
our ECR 12 hours after treatment for persistence of the epistax-
is, and a short Merocel was added to the two already present. In 
3 cases, it occurred just after the programmed nasal dressing re-
moval and required new NP. Three patients had a recurrence of 
epistaxis from the same source of bleeding 8, 17, and 30 days, 
respectively, after the first episode and were treated with NP. 
Two patients in this group underwent bipolar cauterization and 
one treatment with LA while, in the last 4 cases, there was no 
need for other treatment.
Comparison
The results for each procedure are compared in Table 1. Bleed-
ing recurrence was higher in the NP group even if the value was 
not statistically significant (P=0.2935 using Fisher exact test) 
also when considering only patients using anticoagulant therapy 
(P=0.6206) or those not using anticoagulant therapy (P= 
0.3386). Eleven patients complained of pain during execution of 
the procedure in the LA group versus 22 in the NP group; the 
Table 1. Results for each procedure
Patients Procedures Bleeding recurrence Mean pain Mean cost (Euro) 
Lauromacrogol 26 27 3 (11%) 0.6 4.42
Nasal packing 27 27 7 (26%) 3.2 7.36
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highest reported pain value in the LA group was 3 versus 9 in 
the NP group. The mean pain value was statistically higher in 
the NP group: P<0.0001 using the Wilcoxon rank sum test 
(Mann-Whitney U-test). The mean cost for each procedure was 
lower in the LA group (4.42 Euro [EUR] vs. 7.36 EUR for each 
procedure).
 Comparison of the morbidity in the first 72 hours after each 
treatment shows significantly higher discomfort in the NP group 
(Table 2). This was statistically significant when compared with 
the morbidity in the LA group considering nasal congestion 
(P<0.0001), epiphora (P<0.0001) or, in particular, headache/
pain (P<0.0001).
DISCUSSION
The elevated healthcare costs due to the high frequency of epi-
staxis, which is one of the most common otorhinolaryngologic 
emergencies, require the adoption of the most effective and least 
expensive therapeutic strategy to reduce inpatient stay, surgical 
rates and transfusion rates [8]. Another aspect which should be 
considered is the discomfort and pain caused by each of the sev-
eral kinds of treatments proposed for epistaxis [4]. For these 
reasons, it is also important to choose the method best accepted 
by the patients which should have 3 characteristics: minimal dis-
comfort, cost effectiveness and low level of recurrence [4].
 The basic approach to any case of epistaxis consists of three 
steps: identification of the bleeding site, stopping the bleeding 
and identification and treatment of the underlying cause, if any 
[6].
 Submucosal infiltration of LA is a well-established treatment 
which has already proven its effectiveness in HHT or Rendu-Os-
ler-Weber disease [9] being the epistaxis the most frequent clini-
cal manifestation in HHT. Epistaxis results from rupture of the 
telangiectases present in the nasal mucosa, leading when severe, 
to recurrent visits to emergency units, periods in the hospital and 
transfusions, thereby, endangering the physical integrity of pa-
tients and reducing their quality of life [9]. On the basis of the 
data collected by Morais et al. [9] and considering our experience 
in the treatment of HHT with LA injection in the last 7 years, it 
was also decided to try this technique on patients with anterior 
epistaxis. This type of procedure is simple and can easily be per-
formed as an office procedure with local anesthesia. Preparing 
the nose with an anesthetic and a decongestant helps to find the 
site of the bleeding and causes the patient less discomfort [1].
 For many years, the mainstay of treatment for anterior epi-
staxis was NP [6]: this technique is still considered useful when 
it is not possible to identify the bleeding point, even with a nasal 
endoscope [5]. In the majority of patients, when the bleeding 
point in the anterior part of the nose is evident, epistaxis can be 
better controlled with direct cautery [8] without resorting to NP 
[10]. Silver nitrate cautery is also an effective treatment and can 
prevent recurrence [11]. These types of treatment can avoid the 
morbidities associated with NP, including pain, necrosis of the 
nasal ala, hypoxia [6], toxic shock syndrome, septal hematoma 
and abscess, Eustachian tube dysfunction, acute sinusitis, epiph-
ora, hearing loss, dysphagia, displacement of the packing into 
the oropharynx resulting in acute airway obstruction, aspiration 
and respiratory arrest [2].
 The data collected by our study cannot demonstrate a statisti-
cally significant difference in outcome between the 2 arms; how-
ever, for the patients in the LA group, tolerance was better dur-
ing treatment and also during the following days. Only 1 patient 
referred pain for a few days after the injection, no patient pre-
sented epiphora or nasal congestion and the mean pain value 
during the execution of the treatment on a numeric rating scale 
(NRS-11) was clearly lower than the NP group (0.6 vs. 3.2). 
Moreover, in the majority of cases in the LA group, the discom-
fort of NP removal and bleeding risk after NP removal were 
eliminated. No major complications (nasal perforation, septal 
abscesses, etc.) occurred in either group after the first follow-up 
and no complications were reported during the telephone inter-
views. The cost analysis showed that the LA treatment was 
cheaper than NP with a medium cost of 4.42 EUR versus 7.36 
EUR. This is reinforced by the fact that patients with NP abso-
lutely require a second visit to remove the Merocel or Hyal-
uronic acid gauze pads leading to additional cost. On the con-
trary, there is no need for a second visit after LA injection unless 
there is a recurrence of epistaxis. Our results confirmed those 
obtained of Morais et al. [9] regarding the treatment of HHT in 
terms of both efficacy and complications; in their series, only 1 
case of septal perforation was reported in 300 procedures.
 For the above-mentioned reasons, this technique represents a 
viable alternative to the other methods proposed for anterior 
epistaxis treatment. It fully meets the requirements for the ideal 
treatment of epistaxis: good efficacy, well tolerated by the pa-
tient and low cost. Moreover, the use of expensive devices re-
quiring a specific environment, such as in the case of bipolar 
Table 2. Comparison of morbidity between the two procedures
Nasal congestion Epiphora Headache/pain Other
LA NP LA NP LA NP NP
No. of patients presenting 
   symptoms (%)
0 24 (89) 0 17 (63) 1 (4) 18 (67) 4 (15) 
    Sneezing (2); sore throat (2)
Mean value 0–5 0 2.9 0 1.9 2 1.4     Sneezing (2); sore throat (4.5)
LA, lauromacrogol; NP, nasal packing.
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diathermy despite its proven effectiveness, is unnecessary [2,12, 
13]. In our ECR, for example, cauterization can be performed 
only in the operating room leading to higher costs, loss of time 
and resources, and the need to hospitalize the patient.
 A possible alternative to NP and the other surgical techniques 
available at our institution is the use of Floseal (Baxter Health-
care Corp., Zurich, Switzerland). Floseal, a novel hemostatic 
composed of collagen-derived particles and topical bovine-de-
rived thrombin, is a better tolerated, safe and easy alternative to 
NP in patients with acute anterior epistaxis [14]; however, costs 
are higher with Floseal [6].
 The introduction of rigid nasal endoscopes for the diagnosis 
and therapy of sinonasal pathologies also permits using them for 
the treatment of epistaxis because their usefulness in identifying 
the bleeding point [1]. Endoscopic exploration of the nasal cavi-
ty permits more precise identification and treatment of the area 
to be infiltrated, and excludes or reveals other potential points 
of bleeding. With the help of endoscopes, it is also possible to 
treat more posterior sources of bleeding with the LA infiltration 
technique.
 In conclusion, LA infiltration was demonstrated to be a viable 
alternative in anterior epistaxis treatment. It is safe, easy to use, 
and has good efficacy and low costs.
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